Similar articles

• Molecular aspects of Huntington's disease.

  Walling HW, Baldassare JJ, Westfall TC. Walling HW, et al. J Neurosci Res. 1998 Nov 1;54(3):301-8. doi: 10.1002/(SICI)1097-4547(19981101)54:3<301::AID-JNR1>3.0.CO;2-W. J Neurosci Res. 1998. PMID: 9819135 Review.
• Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.

  Truant R, Atwal RS, Burtnik A. Truant R, et al. Prog Neurobiol. 2007 Nov;83(4):211-27. doi: 10.1016/j.pneurobio.2006.11.004. Epub 2007 Jan 22. Prog Neurobiol. 2007. PMID: 17240517 Review.
• Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.

  Nguyen T, Hamby A, Massa SM. Nguyen T, et al. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11840-5. doi: 10.1073/pnas.0502177102. Epub 2005 Aug 8. Proc Natl Acad Sci U S A. 2005. PMID: 16087879 Free PMC article.
• Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates.

  Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, Doi H, Machida Y, Wong HK, Suzuki T, Uchikawa C, Kotliarov Y, Uchida K, Nagao Y, Nagaoka U, Tamaoka A, Oyanagi K, Oyama F, Nukina N. Kotliarova S, et al. J Neurochem. 2005 May;93(3):641-53. doi: 10.1111/j.1471-4159.2005.03035.x. J Neurochem. 2005. PMID: 15836623
• Polyglutamine expansion disturbs the endoplasmic reticulum formation, leading to caspase-7 activation through Bax.

  Ueda M, Li S, Itoh M, Hayakawa-Yano Y, Wang MX, Hayakawa M, Hasebe-Matsubara R, Ohta K, Ohta E, Mizuno A, Hida Y, Matsumoto M, Chen H, Nakagawa T. Ueda M, et al. Biochem Biophys Res Commun. 2014 Jan 24;443(4):1232-8. doi: 10.1016/j.bbrc.2013.12.114. Epub 2014 Jan 2. Biochem Biophys Res Commun. 2014. PMID: 24388981